Neil Cataldi

Info on Twitter is not intended to offer investment advice.

[Neil Cataldi @neilcataldi]

@ClarkSquareCap Check out Michael Lewis on Smartless. Entertaining. Smart. Sentimental. https://t.co/xyeahXo20X

[Neil Cataldi @neilcataldi]

@JosephNebenzahl Several growth opps.

Fiserv products are all ready to go incl Frontstage.

Teams. CI is the one to watch. Needle is starting to move. 90 day sales cycle from launch in March is why bookings started in the last Q.

MaxCloud. Big opp w/converting customers. Also ready to go.

[Neil Cataldi @neilcataldi]

@dunbelievable @AndrewRangeley Earnings on Monday. CC Tuesday AM. Let’s see if the record month of revenue in March carried into and through 2Q. The story continues to get better from when I spoke on the pod.

[Neil Cataldi @neilcataldi]

@benbakhshi @BryanGreenbaum Spun out almost two years ago. Book value has only increased but stock still trades at a huge discount, 50%+. Co has bought a lot of stock back. Catalysts are limited but they could tender for more stock at any time and presumably at a much higher price than where it is today.

[Neil Cataldi @neilcataldi]

@iancassel $INFU is a last mile provider of at home health care. Just signed a MSA with GE that will add $10M+ annually. Several shots on goal for growth. Co guided ‘22 to +15-20% & Ebitda of $24-$27M. Stock trades ~7x today. Co is actively buying back stock as well.

[Neil Cataldi @neilcataldi]

@LukeWolgram It was a great quarter & a call no different than their previous calls. They’re confident. They don’t have to issue guidance & they don’t have to answer every ? in great detail. Name another medtech growing 50%+ w/85%+ margins & minimal inst ownership. Only a matter of time.

[Neil Cataldi @neilcataldi]

@talbottzink Great Q. The dots connect very well for continued strong growth. Hospitals sold into are only 45% of the approved base. New sales reps are driving the growth by "landing" sales from new hospitals in the base, plus "expanding" in the hospitals they're already in.

[Neil Cataldi @neilcataldi]

@iancassel The worst new consumer product idea I’ve seen in years… 😆

[Neil Cataldi @neilcataldi]

@MMMembrado @iancassel I believe management is focused on profitability. The S&M investment has been made. They’ve got many territories covered now; selectively adding more but I wouldn’t expect the pace to continue. 1099 reps create leverage too as the RSM’s cover more of them/geography.

[Neil Cataldi @neilcataldi]

@MMMembrado @iancassel Definitely leverage in the channel w/the RSM’s. Hospital approvals lead to new customers/revenue which leads to even more revenue as they expand from one product to multiple. All of the indicators are trending higher despite Covid which has negatively affected most med tech cos.

[Neil Cataldi @neilcataldi]

@stockspinoffss Definitely on the list of potential catalysts.

[Neil Cataldi @neilcataldi]

$BBXIA. Updating this one again.

O/S declined 15% in '21 from 19.3M to 16.3M. Buybacks will continue as co announced a new 15M share repurchase in January.

Book value is $20.79; +~30% YoY.

Share price is more than 50% below BV @ $9.78.

[Neil Cataldi @neilcataldi]

$BBXIA. Co just repurchased 1.3M shares from a shareholder, likely Angelo Gordon @$11.10/share. Book value increases to ~$20.45. Quite the year for this company buying back its' own stock and yet it is still trading nearly 50% below book value.

[Neil Cataldi @neilcataldi]

$VNRX signed a 28M agreement w $HSKA this week to expand cancer detection in dogs. Per CC, co negotiating w 2 other companies as well.

Global opp, but U.S. TAM likely larger than one would think. 77M dogs. 20M>7 years old. 15M visit a vet annually.

https://t.co/ZAbhf5uJkY

[Neil Cataldi @neilcataldi]

$SMTI Revs grew 55% to 24M during '21. December was a record month despite Covid. Cellerate sold into 471 hospitals; 1100 approved. Telemed pilot expanded to 6 sites. 30 RSM's now.

Hospital approvals remain a key forward indicator. New product launches will add to growth in '22

[Neil Cataldi @neilcataldi]

$SMTI. Earnings takeaways.

1️⃣2Q revenue +112% YoY

2️⃣Cellerate sold into ONLY 300 hospitals but over 900 now APPROVED

3️⃣Regional Sales Managers increased 45% in the Q; 18 to 26.

4️⃣ Key forward indicators = Hospital approvals & RSM’s both strongly pointing higher

[Neil Cataldi @neilcataldi]

$NEPH 4Q CC highlights

HDF on schedule for mid year 510k FDA clearance

New filter win w/national QSR chain; thousand + locations; $250k revs '22

Strategic supplier to two new dialysis cos; $500k revs '22

Commercial discussions w/3 leading firms re water pathogen distribution

[Neil Cataldi @neilcataldi]

@LaughingH20Cap @Captainpowers5 7-11 is without question a nice win… but label heavy lower margin revs. If it’s going to be successful, kitchen efficiencies in restaurants is what intrigues me most. Zippy apparently has Subway already. Would like to see that type of win to further validate it.

[Neil Cataldi @neilcataldi]

@fresearch2017 @LaughingH20Cap Agree on the valuation, but not knowing the terms is a concern. Why would Avery want them selling the same product essentially? And if you ask management, they have no response. The unknown is something to acknowledge as a risk especially when the whole growth story hinges on it.